DOCSLIB.ORG

Establishing Stable Cell Lines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Establishing Stable Cell Lines Establishing Stable Cell Lines 1. Our proprietary expression system for mammalian cells is used. 2. Our stable cell lines are from the single colonies, not from the pool. 3. Many single clones are screened, and three best ones are kept. 4. Functional assay is performed to confirm the clones’ biological function. 5. Time frame: 2 – 3 months for one stable cell line List of In-Stock ACTOne GPCR Stable Clones Transduced Gi-coupled receptors (22) Transduced Gs coupled receptors (34) Cannabinoid receptor 1 (CB1) Vasoactive Intestinal Peptide Receptor 2 (VIPR2) Dopamine Receptor 2 (DRD2) Melanocortin 4 Receptor (MC4R) Melanocortin 5 Receptor (MC5R) Somatostatin Receptor 5 (SSTR5) Parathyroid Hormone Receptor 1 (PTHR1) Adenosine A1 Receptor (ADORA1) Glucagon Receptor (GCGR) Chemokine (C-C motif) receptor 5 (CCR5) Dopamine Receptor 1 (DRD1) Melanin-concentrating Hormone Receptor 1 (MCHR1) Prostaglandin E Receptor 4 (EP4) Vasoactive Intestinal Peptide Receptor 1 (VIPR1) Cannabinoid receptor 2 (CB2) Gastric Inhibitor Peptide Receptor (GIPR) Glutamate receptor, metabotropic 8 (GRM8) Dopamine Receptor 5 (DRD5) Opioid receptor, kappa 1 (OPRK1) Parathyroid Hormone Receptor 2 (PTHR2) Adenosine A3 receptor (ADORA3) 5-hydroxytryptamine (serotonin) receptor 6 (HTR4) Corticotropin Releasing Hormone Receptor 2 (CRHR2) Glutamate receptor, metabotropic 8 (GRM8) Adenylate Cyclase Activating Polypeptide 1 Receptor type I (ADCYAP1R1) Neuropeptide Y Receptor Y1 (NPY1R) Secretin Receptor (SCTR) Neuropeptide Y Receptor Y2 (NPY2R) Follicle Stimulating Hormone Receptor (FSHR) Sphingosine-1-phosphate receptor 1 (EDG1) 5-hydroxytryptamine (serotonin) receptor 6 (HTR6) 5-hydroxytryptamine (serotonin) receptor 7 (HTR7B) Glutamate receptor, metabotropic 7 (GRM7) Glucagon-like peptide 2 receptor (GLP2R) Glutamate receptor, metabotropic 2 (GRM2) Thyroid stimulating hormone receptor (TSHR) Chemokine (C-X-C motif) receptor 4 (CXCR4) Melanocortin 3 Receptor (MC3R) Opiate receptor-like 1 (OPRL1) Arginine Vasopressin Receptor 2 (AVPR2) Angiotensin II receptor-like 1 (AGTRL1) Prostaglandin I2 Receptor (PTGIR) Glucagon-like-1 Receptor (GLPR1) Opioid receptor, mu 1 (OPRM1) Corticotropin Releasing Hormone Receptor 1 (CRHR2) Glutamate receptor, metabotropic 4 (GRM4) Calcitonin receptor-like (CALCRL) Neuropeptide Y Receptor Y4 (NPY4R) Adenosine A2b receptor (ADORA2B) Beta2 Andrenergic Receptor (ADRB2) Prostaglandin D2 receptor (PTGDR) Prostaglandin E receptor 2 (PTGER2) Melanocortin 1 Receptor (MC1R) Calcitonin receptor (CALCR) www.eenzyme.com Adenosine A2a receptor (ADORA2a) Amylin 3 receptor (Amy3R) List of In-Stock ACTOne PDE Stable Clones Phosphodiesterase 10A (PDE10A) Phosphodiesterase 1B (PDE1B) Phosphodiesterase 1C (PDE1C) Phosphodiesterase 2A (PDE2A) Phosphodiesterase 4 (PDE4) Phosphodiesterase 4A (PDE4A) Phosphodiesterase 4B (PDE4B) Phosphodiesterase 4D (PDE4D) www.eenzyme.com.
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • A Guide to Glutamate Receptors
    A guide to glutamate receptors 1 Contents Glutamate receptors . 4 Ionotropic glutamate receptors . 4 - Structure ........................................................................................................... 4 - Function ............................................................................................................ 5 - AMPA receptors ................................................................................................. 6 - NMDA receptors ................................................................................................. 6 - Kainate receptors ............................................................................................... 6 Metabotropic glutamate receptors . 8 - Structure ........................................................................................................... 8 - Function ............................................................................................................ 9 - Group I: mGlu1 and mGlu5. .9 - Group II: mGlu2 and mGlu3 ................................................................................. 10 - Group III: mGlu4, mGlu6, mGlu7 and mGlu8 ............................................................ 10 Protocols and webinars . 11 - Protocols ......................................................................................................... 11 - Webinars ......................................................................................................... 12 References and further reading . 13 Excitatory synapse pathway
    [Show full text]
  • Associations Between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients
    Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients ʈ ʈ ʈ Csaba P. Kovesdy,*† Miklos Z. Molnar,‡§ Maria E. Czira, Anna Rudas, Akos Ujszaszi, Laszlo Rosivall,‡ Miklos Szathmari,¶ Adrian Covic,** Andras Keszei,†† Gabriella Beko,‡‡ ʈ Peter Lakatos,¶ Janos Kosa,¶ and Istvan Mucsi §§ *Division of Nephrology, Salem Veterans Affairs Medical Center, Salem, Virginia; †Division of Nephrology, University of Virginia, Charlottesville, Virginia; ‡Institute of Pathophysiology, Semmelweis University, Budapest, Hungary; §Harold Simmons Center for Chronic Disease Research & Epidemiology, Los Angeles Biomedical Research Institute at ʈ Harbor-University of California–Los Angeles Medical Center, Torrance, California; Institute of Behavioral Sciences, Semmelweis University, Budapest, Hungary; ¶First Department of Internal Medicine, Semmelweis University, Budapest, Hungary; **University of Medicine Gr T Popa, Iasi, Romania; ††Department of Epidemiology, Maastricht University, Maastricht, Netherlands; ‡‡Central Laboratory, Semmelweis University, Budapest, Hungary; and §§Division of Nephrology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada Background and objectives: Obesity is associated with increased parathyroid hormone (PTH) in the general population and in patients with chronic kidney disease (CKD). A direct effect of adipose tissue on bone turnover through leptin production has been suggested, but such an association has not been explored in kidney transplant recipients. Design, setting, participants, & measurements: This study examined associations of serum leptin with PTH and with biomarkers of bone turnover (serum beta crosslaps [CTX, a marker of bone resorption] and osteocalcin [OC, a marker of bone formation]) in 978 kidney transplant recipients. Associations were examined in multivariable regression models. Path analyses were used to determine if the association of leptin with bone turnover is independent of PTH.
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Endocrine System WS19
    Endocrine System Human Physiology Unit 3 Endocrine System • Various glands located throughout the body • Some organs may also have endocrine functions • Endocrine glands/organs synthesize and release hormones • Hormones travel in plasma to target cells Functions of the Endocrine System • Differentiation of nervous and reproductive system during fetal development • Regulation of growth and development • Regulation of the reproductive system • Maintains homeostasis • Responds to changes from resting state Mechanisms of Hormone Regulation • Hormones have different rates and rhythms of secretion • Hormones are regulated by feedback systems to maintain homeostasis • Receptors for hormones are only on specific effector cells • Excretion of hormones vary for steroid hormones and peptide hormones Regulation of Hormone Secretion • Release of hormones occurs in response to • A change from resting conditions • Maintaining a regulated level of hormones or substances • Hormone release is regulated by • Chemical factors (glucose, calcium) • Endocrine factors (tropic hormones, HPA) HPA = Hypothalamic-Pituitary Axis • Neural controls (sympathetic activation) Hormone Feedback Systems Negative feedback maintains hormone concentrations within physiological ranges • Negative feedback • Feedback to one level Loss of • Long-loop Negative Feedback feedback • Feedback to two levels control often leads to • Hypothalamus-Pituitary-Gland Axis pathology Negative Feedback Short-Loop Negative Feedback Long-Loop Negative Feedback Hormone Transport Peptide/Protein Hormones
    [Show full text]
  • Transcriptomic Profiling of Pancreatic Alpha, Beta and Delta Cell Populations Identifies Delta Cells As a Principal Target for Ghrelin in Mouse Islets
    Diabetologia (2016) 59:2156–2165 DOI 10.1007/s00125-016-4033-1 ARTICLE Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets Alice E. Adriaenssens1 & Berit Svendsen2,3 & Brian Y. H. Lam1 & Giles S. H. Yeo1 & Jens J. Holst2,3 & Frank Reimann1 & Fiona M. Gribble 1 Received: 15 March 2016 /Accepted: 1 June 2016 /Published online: 7 July 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract using islets with delta cell restricted expression of the calcium Aims/hypothesis Intra-islet and gut–islet crosstalk are critical reporter GCaMP3, and in perfused mouse pancreases. in orchestrating basal and postprandial metabolism. The aim Results A database was constructed of all genes expressed in of this study was to identify regulatory proteins and receptors alpha, beta and delta cells. The gene encoding the ghrelin underlying somatostatin secretion though the use of receptor, Ghsr, was highlighted as being highly expressed transcriptomic comparison of purified murine alpha, beta and enriched in delta cells. Activation of the ghrelin receptor and delta cells. raised cytosolic calcium levels in primary pancreatic delta Methods Sst-Cre mice crossed with fluorescent reporters were cells and enhanced somatostatin secretion in perfused used to identify delta cells, while Glu-Venus (with Venus re- pancreases, correlating with a decrease in insulin and gluca- ported under the control of the Glu [also known as Gcg]pro- gon release. The inhibition of insulin secretion by ghrelin was moter) mice were used to identify alpha and beta cells.
    [Show full text]
  • Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission
    The Journal of Neuroscience, October 14, 2015 • 35(41):14057–14069 • 14057 Neurobiology of Disease Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission Alexandra Alvarsson,1* Xiaoqun Zhang,1* Tiberiu L Stan,1 Nicoletta Schintu,1 Banafsheh Kadkhodaei,2 Mark J. Millan,3 Thomas Perlmann,2,4 and Per Svenningsson1 1Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden, 2Ludwig Institute for Cancer Research, SE-17177 Stockholm, Sweden, 3Pole of Innovation in Neuropsychiatry, Institut de Recherches Servier, Centre de Recherches de Croissy, Paris 87290, France, and 4Department of Cell and Molecular Biology, Karolinska Institutet, SE-17177 Stockholm, Sweden Parkinson’s disease (PD) is a movement disorder characterized by a progressive loss of nigrostriatal dopaminergic neurons. Restoration of dopamine transmission by L-DOPA relieves symptoms of PD but causes dyskinesia. Trace Amine-Associated Receptor 1 (TAAR1) modulates dopaminergic transmission, but its role in experimental Parkinsonism and L-DOPA responses has been neglected. Here, we report that TAAR1 knock-out (KO) mice show a reduced loss of dopaminergic markers in response to intrastriatal 6-OHDA administra- tion compared with wild-type (WT) littermates. In contrast, the TAAR1 agonist RO5166017 aggravated degeneration induced by intra- striatal6-OHDAinWTmice.Subchronic L-DOPAtreatmentofTAAR1KOmiceunilaterallylesionedwith6-OHDAinthemedialforebrain bundle resulted in more pronounced rotational behavior and dyskinesia than in their WT counterparts. The enhanced behavioral sensitization to L-DOPA in TAAR1 KO mice was paralleled by increased phosphorylation of striatal GluA1 subunits of AMPA receptors. Conversely, RO5166017 counteracted both L-DOPA-induced rotation and dyskinesia as well as AMPA receptor phosphorylation.
    [Show full text]
  • Novel Drug-Like Somatostatin Receptor 4 Agonists Are Potential Analgesics for Neuropathic Pain
    International Journal of Molecular Sciences Article Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic Pain 1,2, 3, 1,2 4 1,2 Boglárka Kántás y, Rita Börzsei y, Éva Sz˝oke ,Péter Bánhegyi , Ádám Horváth , 1,2 1,2 1 1,2, Ágnes Hunyady , Éva Borbély , Csaba Hetényi , Erika Pintér y and 1,2, , Zsuzsanna Helyes * y 1 Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Szigeti str. 12, H-7624 Pécs, Hungary 2 Szentágothai Research Centre and Centre for Neuroscience, University of Pécs, Ifjúság str. 20, H-7624 Pécs, Hungary 3 Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti str. 12, H-7624 Pécs, Hungary 4 Avicor Ltd., Herman Ottó str. 15, H-1022 Budapest, Hungary * Correspondence: [email protected] These authors contributed equally to this work. y Received: 14 October 2019; Accepted: 9 December 2019; Published: 11 December 2019 Abstract: Somatostatin released from the capsaicin-sensitive sensory nerves mediates analgesic and anti-inflammatory effects via the somatostatin sst4 receptor without endocrine actions. Therefore, sst4 is considered to be a novel target for drug development in pain including chronic neuropathy, which is an emerging unmet medical need. Here, we examined the in silico binding, the sst4-linked G-protein activation on stable receptor expressing cells (1 nM to 10 µM), and the effects of our novel pyrrolo-pyrimidine molecules in mouse inflammatory and neuropathic pain models. All four of the tested compounds (C1–C4) bind to the same binding site of the sst4 receptor with similar interaction energy to high-affinity reference sst4 agonists, and they all induce G-protein activation.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Peptide, Peptidomimetic and Small Molecule Based Ligands Targeting Melanocortin Receptor System
    PEPTIDE, PEPTIDOMIMETIC AND SMALL MOLECULE BASED LIGANDS TARGETING MELANOCORTIN RECEPTOR SYSTEM By ALEKSANDAR TODOROVIC A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2006 Copyright 2006 by Aleksandar Todorovic This document is dedicated to my family for everlasting support and selfless encouragement. ACKNOWLEDGMENTS I would like to thank and sincerely express my appreciation to all members, former and past, of Haskell-Luevano research group. First of all, I would like to express my greatest satisfaction by working with my mentor, Dr. Carrie Haskell-Luevano, whose guidance, expertise and dedication to research helped me reaching the point where I will continue the science path. Secondly, I would like to thank Dr. Ryan Holder who has taught me the principles of solid phase synthesis and initial strategies for the compounds design. I would like to thank Mr. Jim Rocca for the help and all necessary theoretical background required to perform proton 1-D NMR. In addition, I would like to thank Dr. Zalfa Abdel-Malek from the University of Cincinnati for the collaboration on the tyrosinase study project. Also, I would like to thank the American Heart Association for the Predoctoral fellowship that supported my research from 2004-2006. The special dedication and thankfulness go to my fellow graduate students within the lab and the department. iv TABLE OF CONTENTS page ACKNOWLEDGMENTS ................................................................................................
    [Show full text]
  • Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
    International Journal of Molecular Sciences Review Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System Shenglong Zou and Ujendra Kumar * Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-604-827-3660; Fax: +1-604-822-3035 Received: 9 February 2018; Accepted: 11 March 2018; Published: 13 March 2018 Abstract: The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. The CB1R is the prominent subtype in the central nervous system (CNS) and has drawn great attention as a potential therapeutic avenue in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Furthermore, cannabinoids also modulate signal transduction pathways and exert profound effects at peripheral sites. Although cannabinoids have therapeutic potential, their psychoactive effects have largely limited their use in clinical practice. In this review, we briefly summarized our knowledge of cannabinoids and the endocannabinoid system, focusing on the CB1R and the CNS, with emphasis on recent breakthroughs in the field. We aim to define several potential roles of cannabinoid receptors in the modulation of signaling pathways and in association with several pathophysiological conditions. We believe that the therapeutic significance of cannabinoids is masked by the adverse effects and here alternative strategies are discussed to take therapeutic advantage of cannabinoids. Keywords: cannabinoid; endocannabinoid; receptor; signaling; central nervous system 1. Introduction The plant Cannabis sativa, better known as marijuana, has long been used for medical purpose throughout human history.
    [Show full text]